Get notified when APMD files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Red Flags Detected

  • Going Concern (unchanged) — Substantial doubt about ability to continue as a going concern remains, with no financial deterioration disclosed.
  • Material Weakness (new) — Material weakness in internal controls over financial reporting for fiscal years 2025 and 2024 remains under remediation.
APMD APMD S-1/A

APMD's FDA review advances with Feb 2027 PDUFA date; IPO terms set at $15/share

Filed July 27, 2026 · Compared to S-1 Jul 10, 2026 · ~1 min read

Key Changes

  • high

    FDA accepted the NDA for Oxnimbi in July 2026 and set a PDUFA goal date of February 28, 2027, a concrete regulatory milestone.

    Business: FDA review status view on EDGAR →
  • high

    IPO terms finalized: 10M shares at $15.00, with net proceeds of $134.6M (or $155.5M if underwriters' option fully exercised).

    Use of Proceeds verify on EDGAR →
  • high

    New investors face immediate dilution of $8.22 per share, with pro forma net tangible book value of $6.78 per share after the offering.

    Dilution verify on EDGAR →

2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (FPS 10-K) is open in full — no account needed.

Partner

Trade APMD commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?
View original filing on SEC.gov

Figures/quotes linked to EDGAR · Narrative written by AI · Aug 30, 2026 · How we verify